top of page

Basilea Pharmaceutica

28 April 2025
Revised Outlook
Going for Growth

18 February 2025
2024 full-year results
Another year of strong execution

16 December 2024
Ceftobiprole agreement
Partner secured

23 October 2024
Incorporating BARDA
A Perfect Match

29 August 2024
Revised outlook and upgrades
Creating an anti-infective powerhouse

13 August 2024
H1 2024 results
Momentum Building

4 April 2024
Zevtera
FDA approval

28 February 2024
Pipeline potential
Anti-infectives ascendancy

5 January 2024
Portfolio update
A year of plenty

31 October 2023
Tonabacase agreement
Novel antibacterial acquisition

19 October 2023
BAL-2062 acquisition
Novel antifungal acquired

14 September 2023
Beyond Cresemba
A bright future beckons

15 August 2023
2023 H1 results
Company guidance raised

15 March 2023
Profitability and prospects
An anti-infectives future

14 February 2023
2022 full-year results
Successful transformation

9 November 2022
2023 heralds a new era
Sustainable Profitability

7 June 2022
Anti-infectives prospects
Important period ahead

10 March 2022
Strategic change
Refocusing on anti-infectives

19 November 2021
Update on derazantinib
Can derazantinib be class leading?

1 September 2021
Post H1 Results update
Firing on all fronts

6 July 2021
Lisavanbulin revisited
Showing lots of promise

31 May 2021
Update on derazantinib clinical programs
Establishing optimum positioning

6 May 2021
Ceftobiprole
Bacteraemia is the key

24 March 2021
FIDES-01 Interim results
Derazantinib differentiation apparent

22 February 2021
Lisavanbulin
Lisavanbulin in Focus

16 February 2021
Full Year 2020
Solid results and more to come

21 December 2020
Derazantinib
The overlooked FGFR inhibitor

19 October 2020 
Initiation of coverage
The best is yet to come

Calvine Partners LLP is authorised and regulated by the Financial Conduct Authority

Calvine Partners LLP, Partnership No. SO306987

Registered in Scotland: 23 Melville Street, Edinburgh, EH3 7PE

Privacy Policy

Calvine Partners
bottom of page